Literature DB >> 27993848

Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.

Angelo Iacobino1, Giovanni Piccaro2, Federico Giannoni1, Alessandro Mustazzolu1, Lanfranco Fattorini3.   

Abstract

The activities of rifampin, rifapentine, bedaquiline, PA-824, clofazimine, nitazoxanide, isoniazid, amikacin, moxifloxacin, niclosamide, thioridazine, and pyrazinamide were tested against nonreplicating (dormant) Mycobacterium tuberculosis H37Rv under conditions of hypoxia at pHs 5.8 and 7.3, mimicking environments of cellular granulomas and caseous granulomas, respectively. At pH 5.8, several drugs killed dormant bacilli, with the best being rifampin and rifapentine. At pH 7.3, only rifampin and rifapentine efficiently killed dormant bacilli, while all other drugs showed little activity.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosis; dormancy; hypoxia; killing; pH; rifampin; rifapentine; tuberculosis

Mesh：

Substances：

Year:  2017        PMID： 27993848      PMCID： PMC5328545          DOI： 10.1128/AAC.02296-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

Review 2.  Latent Mycobacterium tuberculosis infection.

Authors:  Haileyesus Getahun; Alberto Matteelli; Richard E Chaisson; Mario Raviglione
Journal:  N Engl J Med       Date:  2015-05-28       Impact factor: 91.245

3.  Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Authors:  Giovanni Piccaro; Federico Giannoni; Perla Filippini; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 4.  Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Leila C Kahwati; Cynthia Feltner; Michael Halpern; Carol L Woodell; Erin Boland; Halle R Amick; Rachel Palmieri Weber; Daniel E Jonas
Journal:  JAMA       Date:  2016-09-06       Impact factor: 56.272

Review 5.  The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Authors:  Véronique Dartois
Journal:  Nat Rev Microbiol       Date:  2014-02-03       Impact factor: 60.633

Review 6.  Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

Authors:  Alimuddin Zumla; Jeremiah Chakaya; Rosella Centis; Lia D'Ambrosio; Peter Mwaba; Matthew Bates; Nathan Kapata; Thomas Nyirenda; Duncan Chanda; Sayoki Mfinanga; Michael Hoelscher; Markus Maeurer; Giovanni Battista Migliori
Journal:  Lancet Respir Med       Date:  2015-03-09       Impact factor: 30.700

Review 7.  Mycobacterium tuberculosis: success through dormancy.

Authors:  Martin Gengenbacher; Stefan H E Kaufmann
Journal:  FEMS Microbiol Rev       Date:  2012-03-08       Impact factor: 16.408

8.  Prediction of Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Fabio Zuccotto; Ho Hsinpin; Lars Sandberg; Laura E Via; Gwendolyn A Marriner; Thierry Masquelin; Paul Wyatt; Peter Ray; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2016-07-06       Impact factor: 5.084

9.  Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Authors:  Jean-Philippe Lanoix; Thomas Ioerger; Aimee Ormond; Firat Kaya; James Sacchettini; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

10.  Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism.

Authors:  Mi-Jeong Kim; Helen C Wainwright; Michael Locketz; Linda-Gail Bekker; Gabriele B Walther; Corneli Dittrich; Annalie Visser; Wei Wang; Fong-Fu Hsu; Ursula Wiehart; Liana Tsenova; Gilla Kaplan; David G Russell
Journal:  EMBO Mol Med       Date:  2010-07       Impact factor: 12.137
View more
  5 in total

1.  The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.

Authors:  Angelo Iacobino; Federico Giannoni; Manuela Pardini; Giovanni Piccaro; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  HflX is a GTPase that controls hypoxia-induced replication arrest in slow-growing mycobacteria.

Authors:  Jie Yin Grace Ngan; Swathi Pasunooti; Wilford Tse; Wei Meng; So Fong Cam Ngan; Huan Jia; Jian Qing Lin; Sze Wai Ng; Muhammad Taufiq Jaafa; Su Lei Sharol Cho; Jieling Lim; Hui Qi Vanessa Koh; Noradibah Abdul Ghani; Kevin Pethe; Siu Kwan Sze; Julien Lescar; Sylvie Alonso
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 12.779

Review 3.  The Role of Complement System and the Immune Response to Tuberculosis Infection.

Authors:  Heena Jagatia; Anthony G Tsolaki
Journal:  Medicina (Kaunas)       Date:  2021-01-20       Impact factor: 2.430

4.  Activity of Drug Combinations against Mycobacterium abscessus Grown in Aerobic and Hypoxic Conditions.

Authors:  Alessio Lanni; Emanuele Borroni; Angelo Iacobino; Cristina Russo; Leonarda Gentile; Lanfranco Fattorini; Federico Giannoni
Journal:  Microorganisms       Date:  2022-07-14

5.  Impaired Succinate Oxidation Prevents Growth and Influences Drug Susceptibility in Mycobacterium tuberculosis.

Authors:  Cara Adolph; Matthew B McNeil; Gregory M Cook
Journal:  mBio       Date:  2022-07-20       Impact factor: 7.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.